Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry warehouse away from incompatible substances. Protect from light and moisture. Shipping: Deliver to worldwide by FedEx / DHL Express. Provide fast and reliable delivery. Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 3-[3-(Trifluoromethyl)phenyl]-1-Propanol (CAS: 78573-45-2) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase 3-[3-(Trifluoromethyl)phenyl]-1-Propanol, Please contact: alvin@ruifuchem.comDescription:
Package/Storage/Shipping:
| Chemical Name | 3-[3-(Trifluoromethyl)phenyl]-1-Propanol |
| Synonyms | 3-[3-(Trifluoromethyl)phenyl]propanol; 3-(3'-Trifluoromethylphenyl)propanol; 3-(3-(Trifluoromethyl)phenyl)propan-1-ol; 3-(Trifluoromethyl)benzene propanol |
| Impurity | USP Cinacalcet Related Compound E |
| Stock Status | In Stock, Commercial Scale |
| CAS Number | 78573-45-2 |
| Molecular Formula | C10H11F3O |
| Molecular Weight | 204.19 g/mol |
| Boiling Point | 60℃/1.13mmHg(lit.) |
| Flash Point | 105℃ |
| Storage Temp. | Cool & Dry Place |
| COA & MSDS | Available |
| Category | Pharmaceutical Intermediates |
| Brand | Ruifu Chemical |
Advantages:
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals. Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc. Advantages? Superior quality, affordable price, professional services and technical support, fast delivery. Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc. Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers. Factory Audit? Factory audit welcome. Please make an appointment in advance. MOQ? No MOQ. Small order is acceptable. Delivery Time? If within stock, three days delivery guaranteed. Transportation? By Express (FedEx, DHL), by Air, by Sea. Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided. Custom Synthesis? Can provide custom synthesis services to best fit your research needs. Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.FAQ:
Stable Supply: Maintain reasonable stock
Professional Service: One stop purchasing service
Technical Support: Technology solution available
Custom Synthesis Service: Ranged from grams to kilos
Fast Delivery: If within stock, three days delivery guaranteed
High Quality: Established a complete quality assurance system
Sufficient Capacity: Sufficient facilities and technicians
OEM Package: Custom package and label available
Specifications:
| Items | Inspection Standards | Results |
| Appearance | Colorless to Light Yellow Liquid | Complies |
| Water by Karl Fischer | <0.50% | 0.07% |
| Purity / Analysis Method | >99.0% (HPLC) | 99.60% |
| Refractive Index n20/D | 1.462~1.466 | Complies |
| Density (20℃) | 1.212~1.216 | Complies |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1 H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested & complies with the specifications | |
| Application | Intermediate of Cinacalcet Hydrochloride (CAS: 364782-34-3) | |
Application:
3-[3-(Trifluoromethyl)phenyl]-1-Propanol (CAS: 78573-45-2) is an intermediate in the synthesis of Cinacalcet Hydrochloride (CAS: 364782-34-3). Cinacalcet is the first entry in a new class of therapeutic agents called the calcimimetics. It was launched as an oral treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in patients with parathyroid carcinoma. SHPT is associated with increased parathyroid hormone (PTH) secretion, which is triggered by low serum levels of calcium resulting from the failure of the kidney to clear phosphorous from the body and its inability to produce sufficient quantities of vitamin D. The consequences of increased PTH include stimulation of osteoclastic activity, cortical bone resorption and marrow fibrosis. PTH secretion is primarily regulated by the calcium-sensing receptor (CaR), which is located on the surface of the chief cell of the parathyroid gland. Calcimimetics bind to CaR and increase the sensitivity of CaR to extracellular calcium, thereby enabling its activation at subnormal levels of serum calcium. As a result, in the presence of these agents, the low levels of endogenous calcium in patients with renal failure are able to exert a suppressive effect on PTH secretion. Parathyroid carcinoma is also associated with elevated PTH levels, which are driven by autonomous parathyroid gland activity and subsequently lead to hypercalcemia. Although surgical resection is the primary therapy for treating hypercalcemia in parathyroid carcinoma patients, calcimimetics offer a nonsurgical alternative for patients with failed parathyroidectomy, metastatic parathyroid carcinoma, or high surgical risk.